AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29665762 — intervention group
Group type: EXPERIMENTAL
Intervention: B complex preparation containing a range of B vitamins
Number of subjects: 100
Study 29665762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26755225 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sodium ascorbate (SA) gel, delayed bonding (1-week)
Number of subjects: 140
Study 26755225 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate bonding after bleaching
Number of subjects: 140
Study 26755225 — intervention group
Group type: COMPARATOR
Intervention: Adper Single Bond 2 total-etch and Clearfil Tri S Bond self-etch adhesives (control)
Number of subjects: 140
Study 26755225 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching with 35% Beyond Max and 38% Opalescence Xtra Boost
Number of subjects: 140
Study 24141646 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg
Number of subjects: 36
Study 24141646 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg
Number of subjects: 36
Study 24141646 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g
Number of subjects: 36
Study 24141646 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 36
Study 23279702 — intervention group
Group type: EXPERIMENTAL
Intervention: 1540-nm nonablative fractional laser therapy (NAFL), four treatments at monthly intervals
Number of subjects: 18
Study 23279702 — intervention group
Group type: COMPARATOR
Intervention: Control side (untreated)
Number of subjects: 18
Study 23279702 — intervention group
Group type: EXPERIMENTAL
Intervention: 1540-nm nonablative fractional laser therapy (NAFL)
Number of subjects: 18
Study 20837777 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect misattribution procedure (AMP)
Number of subjects: 0
Study 18827046 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapler closure technique
Number of subjects: 336
Study 18827046 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn closure technique
Number of subjects: 336
Study 17177902 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed exercises for 30 min every day for 6 weeks
Number of subjects: 35
Study 17177902 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 35
Study 17177902 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (exercise and control)
Number of subjects: 35
Study 12940928 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 22
Study 10823761 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin‐2 (IL‐2) at doses of 1.5 MIU, 4.5 MIU, and 7.5 MIU per dose, delivered by twice‐daily injection for 5 consecutive days every 8 weeks
Number of subjects: 73
Study 10823761 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin‐2 (IL‐2) at 4.5 MIU
Number of subjects: 73
Study 10823761 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin‐2 (IL‐2) at 7.5 MIU
Number of subjects: 73
Study 10823761 — intervention group
Group type: COMPARATOR
Intervention: Control group (ART alone)
Number of subjects: 73
Study 10823761 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin‐2 (IL‐2) at 1.5 MIU
Number of subjects: 73
Study 8880038 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono-diet (high-fat, monounsaturated-fat enriched)
Number of subjects: 31
Study 8880038 — intervention group
Group type: COMPARATOR
Intervention: Poly-diet (reduced-fat, polyunsaturated-fat enriched)
Number of subjects: 31
Study 8880038 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono-diet
Number of subjects: 31
Study 8880038 — intervention group
Group type: COMPARATOR
Intervention: Poly-diet
Number of subjects: 31
Study 8880038 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono-diet and Poly-diet
Number of subjects: 31
Study 8315204 — intervention group
Group type: EXPERIMENTAL
Intervention: D3X4 lens
Number of subjects: 15
Study 8315204 — intervention group
Group type: COMPARATOR
Intervention: Novalens (Ocu‐Tec)
Number of subjects: 15
Study 8315204 — intervention group
Group type: COMPARATOR
Intervention: ENVISION (Polymer Technology Corporation)
Number of subjects: 15
Study 3719618 — intervention group
Group type: EXPERIMENTAL
Intervention: CM
Number of subjects: 175
Study 3719618 — intervention group
Group type: COMPARATOR
Intervention: PH
Number of subjects: 175
Study 3719618 — intervention group
Group type: COMPARATOR
Intervention: IG
Number of subjects: 175
Study 30086592 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic Urethral Lift (PUL; Urolift)
Number of subjects: 0
Study 30086592 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary Implantable Nitinol Device (TIND)
Number of subjects: 0
Study 30086592 — intervention group
Group type: COMPARATOR
Intervention: Rezũm (ablative technology)
Number of subjects: 0
Study 30086592 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation (AquaBeam)
Number of subjects: 0
Study 27270858 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment (valproic acid, fluoxetine, risperidone, lorazepam) for 12 weeks
Number of subjects: 89
Study 24886647 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS (IVF + TEAS)
Number of subjects: 2220
Study 24886647 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) (IVF + EA)
Number of subjects: 2220
Study 24886647 — intervention group
Group type: COMPARATOR
Intervention: Control (only IVF)
Number of subjects: 2220
Study 25409597 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportal technique
Number of subjects: 80
Study 25409597 — intervention group
Group type: COMPARATOR
Intervention: Transtibial technique
Number of subjects: 80
Study 22578793 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (100 mg/m², days 1-7 of 1 week on, 1 week off cycles)
Number of subjects: 412
Study 22578793 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (60.0 Gy over 6-7 weeks in 30 fractions of 1.8-2.0 Gy)
Number of subjects: 412
Study 22578793 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (with MGMT promoter methylation)
Number of subjects: 412
Study 22578793 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (with MGMT promoter methylation)
Number of subjects: 412
Study 22578793 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (without MGMT promoter methylation)
Number of subjects: 412
Study 22578793 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (without MGMT promoter methylation)
Number of subjects: 412
Study 22578793 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide
Number of subjects: 412
Study 22578793 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 412
Study 20618554 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% gel
Number of subjects: 52
Study 20618554 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 17554104 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-row suture anchor technique
Number of subjects: 60
Study 17554104 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-row suture anchor technique
Number of subjects: 60
Study 15774531 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-mediated glucose clearance in arm (1 pmol min-1 kg-1)
Number of subjects: 12
Study 15774531 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-mediated glucose clearance in leg (1 pmol min-1 kg-1)
Number of subjects: 12
Study 15774531 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal glucose clearance in arm
Number of subjects: 12
Study 15774531 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal glucose clearance in leg
Number of subjects: 12
Study 15774531 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow in arm
Number of subjects: 12
Study 15774531 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow in leg
Number of subjects: 12
Study 11938697 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose (600 mg) of albendazole with fatty food
Number of subjects: 0
Study 11938697 — intervention group
Group type: COMPARATOR
Intervention: Mebendazole (100 mg, twice a day, fasting state)
Number of subjects: 0
Study 10541425 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA-HFA 450, 900, or 1800 microg/day
Number of subjects: 538
Study 10541425 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA-CFC 450 or 900 microg/day
Number of subjects: 538
Study 10541425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538
Study 8708885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lipid (IVL) administration on day 5
Number of subjects: 64
Study 8708885 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lipid (IVL) administration on day 14
Number of subjects: 64
Study 1824799 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day of sodium clodronate given intravenously as a 3‐hour infusion for 20 days
Number of subjects: 28
Study 1824799 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day of sodium clodronate given intravenously as a 3‐hour infusion for 10 days
Number of subjects: 28
Study 1824799 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day of sodium clodronate given intravenously as a 3‐hour infusion for both groups
Number of subjects: 28
Study 6653647 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg t.i.d.
Number of subjects: 9
Study 6653647 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined verapamil (80 mg t.i.d.) and quinidine (160 mg t.i.d.)
Number of subjects: 9
Study 6653647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30613911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 29274893 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based treatment (ABT)
Number of subjects: 0
Study 29274893 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral treatment (SBT)
Number of subjects: 0
Study 26829478 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized pre-operative telephone checklist administered between 7 and 3 days before surgery.
Number of subjects: 3900
Study 26829478 — intervention group
Group type: COMPARATOR
Intervention: Standard management alone (control group).
Number of subjects: 3900
Study 25146896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fomentation combined with Chinese herbal
Number of subjects: 76
Study 25146896 — intervention group
Group type: COMPARATOR
Intervention: Fomentation without any medicine (Control Group)
Number of subjects: 76
Study 22486344 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol cigarette
Number of subjects: 9
Study 22486344 — intervention group
Group type: COMPARATOR
Intervention: Nonmenthol cigarette
Number of subjects: 9
Study 20809682 — intervention group
Group type: EXPERIMENTAL
Intervention: Current catheter model (soft cannula) during the initial 1-month period (P1)
Number of subjects: 45
Study 20809682 — intervention group
Group type: EXPERIMENTAL
Intervention: New Accu-Chek FlexLink catheter model during the 3-month period (P2)
Number of subjects: 45
Study 20809682 — intervention group
Group type: EXPERIMENTAL
Intervention: Current catheter model (soft cannula) during P1
Number of subjects: 45
Study 20809682 — intervention group
Group type: EXPERIMENTAL
Intervention: New Accu-Chek FlexLink catheter model during P2
Number of subjects: 45
Study 17984186 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (30 mg three times per week, for up to 12 weeks)
Number of subjects: 297
Study 17984186 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil (40 mg/m2 every 28 days, for up to 12 months)
Number of subjects: 297
Study 15918057 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/day)
Number of subjects: 31
Study 15918057 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg/day)
Number of subjects: 31
Study 15918057 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of valsartan (80 mg/day) and perindopril (4 mg/day)
Number of subjects: 31
Study 11863242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 69
Study 11863242 — intervention group
Group type: EXPERIMENTAL
Intervention: Interoceptive exposure (IE)
Number of subjects: 69
Study 9804712 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge (discharge two days after surgery)
Number of subjects: 100
Study 9804712 — intervention group
Group type: COMPARATOR
Intervention: Standard management (discharge after removal of drain)
Number of subjects: 100
Study 7666645 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal scleral incision
Number of subjects: 162
Study 7666645 — intervention group
Group type: COMPARATOR
Intervention: 12-h limbal incision
Number of subjects: 162
Study 1341206 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate 75 mg daily for 6 months
Number of subjects: 23
Study 1341206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 1341206 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine combined with oxygen (8-10 L/min)
Number of subjects: 23
Study 6605310 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinoridine 200 mg
Number of subjects: 6
Study 6605310 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinoridine 400 mg
Number of subjects: 6
Study 6605310 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinoridine 800 mg
Number of subjects: 6
Study 6605310 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinoridine 200 mg (patients with renal disease)
Number of subjects: 6
Study 30889207 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometer volume and pressure oriented (IS-vp)
Number of subjects: 12
Study 29716563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry extract (2 × 18.5 mg PACs per day)
Number of subjects: 148
Study 29716563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry extract (37 mg PACs per day)
Number of subjects: 148
Study 29716563 — intervention group
Group type: COMPARATOR
Intervention: Control dose (2 × 1 mg PACs per day)
Number of subjects: 148
Study 29716563 — intervention group
Group type: COMPARATOR
Intervention: Control dose (2 mg PACs per day)
Number of subjects: 148
Study 26821189 — intervention group
Group type: EXPERIMENTAL
Intervention: PG201 (600mg, 300mg twice daily)
Number of subjects: 124
Study 26821189 — intervention group
Group type: COMPARATOR
Intervention: SKI306X (600mg, 200mg thrice daily)
Number of subjects: 124
Study 26821189 — intervention group
Group type: EXPERIMENTAL
Intervention: PG201
Number of subjects: 124
Study 26821189 — intervention group
Group type: COMPARATOR
Intervention: SKI306X
Number of subjects: 124
Study 23518215 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (MP) at 32 mg/day for seven days
Number of subjects: 40
Study 23518215 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (MP) at 1 mg/kg/day for four days and 0.5 mg/kg/day for three days
Number of subjects: 40
Study 23518215 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (MP)
Number of subjects: 40
Study 23518215 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (MP)
Number of subjects: 40
Study 22217258 — intervention group
Group type: EXPERIMENTAL
Intervention: Gyejibongnyeong-hwan (GJBNH), taken three times per day for two menstrual cycles
Number of subjects: 100
Study 22217258 — intervention group
Group type: COMPARATOR
Intervention: Placebo, taken three times per day for two menstrual cycles
Number of subjects: 100
Study 22217258 — intervention group
Group type: EXPERIMENTAL
Intervention: Gyejibongnyeong-hwan (GJBNH)
Number of subjects: 100
Study 22217258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19356394 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (XM02) at 5 microg/kg
Number of subjects: 56
Study 19356394 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (XM02) at 10 microg/kg
Number of subjects: 56
Study 19356394 — intervention group
Group type: COMPARATOR
Intervention: Reference product (Neupogen) at 5 microg/kg
Number of subjects: 56
Study 19356394 — intervention group
Group type: COMPARATOR
Intervention: Reference product (Neupogen) at 10 microg/kg
Number of subjects: 56
Study 17439651 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-specific training for 12 weeks
Number of subjects: 12
Study 15893007 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin (Gem/Cis)
Number of subjects: 612
Study 15893007 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/Carboplatin (Pac/Carbo)
Number of subjects: 612
Study 15893007 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine/Cisplatin (Vin/Cis)
Number of subjects: 612
Study 12044859 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinpocetine (20 mg in 500 ml saline)
Number of subjects: 43
Study 12044859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 ml saline)
Number of subjects: 43
Study 9754168 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 52
Study 9754168 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 52
Study 7652726 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of magnesium
Number of subjects: 58186
Study 2530745 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable monofilament polyglyconate (PG) (Maxon*)
Number of subjects: 167
Study 2530745 — intervention group
Group type: COMPARATOR
Intervention: Non-absorbable polyamide (PA) (Ethilon*)
Number of subjects: 167
Study 1190614 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate aerosol
Number of subjects: 18
Study 1190614 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol hydrochloride aerosol
Number of subjects: 18
Study 1190614 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 18
Study 29329154 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodic stimulation (a-tDCS)
Number of subjects: 15
Study 29329154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodic stimulation (c-tDCS)
Number of subjects: 15
Study 29329154 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study 30779795 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education intervention
Number of subjects: 0
Study 30779795 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28419462 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast (selective phosphodiesterase 4 inhibitor)
Number of subjects: 0
Study 28419462 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 0
Study 28419462 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 25978942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol cream
Number of subjects: 25
Study 25978942 — intervention group
Group type: COMPARATOR
Intervention: Control cream (without mannitol)
Number of subjects: 25
Study 23200117 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted treadmill training (RATT)
Number of subjects: 16
Study 23200117 — intervention group
Group type: EXPERIMENTAL
Intervention: Manually assisted treadmill training (MATT)
Number of subjects: 16
Study 21751243 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI lie detection evidence
Number of subjects: 330
Study 21751243 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygraph evidence
Number of subjects: 330
Study 21751243 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal facial imaging
Number of subjects: 330
Study 21751243 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no lie detection evidence)
Number of subjects: 330
Study 18929592 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated complex Chinese characters
Number of subjects: 0
Study 18929592 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated simple Chinese characters
Number of subjects: 0
Study 18929592 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex characters with flankers of different complexity groups
Number of subjects: 0
Study 18929592 — intervention group
Group type: COMPARATOR
Intervention: Complex characters with flankers of the same complexity group
Number of subjects: 0
Study 16475633 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine with fentanyl (20 microg) at a conventional high dose of 0.07 mg cm(‐1) (group 1)
Number of subjects: 62
Study 16475633 — intervention group
Group type: COMPARATOR
Intervention: 0.25% levobupivacaine with fentanyl (20 microg) and epidural volume extension with 6 mL of saline (group 2)
Number of subjects: 62
Study 15005765 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine
Number of subjects: 0
Study 15005765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11189545 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure (V.A.C.) therapy
Number of subjects: 10
Study 11189545 — intervention group
Group type: COMPARATOR
Intervention: Saline-moistened gauze
Number of subjects: 10
Study 9052356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine
Number of subjects: 16
Study 9052356 — intervention group
Group type: COMPARATOR
Intervention: Intranasal saline
Number of subjects: 16
Study 9728231 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate via Autohaler
Number of subjects: 181
Study 9728231 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate via metered dose inhaler (MDI)
Number of subjects: 181
Study 3489445 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 500 mg twice a day and dipyridamole 75 mg three times a day
Number of subjects: 442
Study 3489445 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 442
Study 30950493 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (20/mg/kg single dose)
Number of subjects: 30
Study 30950493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30950493 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 30
Study 30316695 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1–4 mg kg−1)
Number of subjects: 48
Study 30316695 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone (0.5–2 mg kg−1)
Number of subjects: 48
Study 30316695 — intervention group
Group type: COMPARATOR
Intervention: Both propofol and alfaxalone
Number of subjects: 48